BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld MedTech
Home
» Agendia receives new FDA clearance for MammaPrint
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Agendia receives new FDA clearance for MammaPrint
Feb. 11, 2015
By
Amanda Pedersen
No Comments
Molecular diagnostics company Agendia (Irvine, California) reported that it has received FDA 510(k) clearance for its MammaPrint breast cancer recurrence test in FFPE (formalin-fixed paraffin embedded) tissue.
BioWorld MedTech